REGN
Regeneron Pharmaceuticals
$776.43
▲ 0.6%Updated Aug 7, 11:30 AM ET
REGN at a glance — five pillars scored 0–100 from real filed financials.
Overall: Favorable · 69/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 18.8% over the last 12 months
Market Cap
$68.59B
P/E
18.36x
Forward P/E (est.)
17.59x
ROE
14.3%
Revenue Growth
5.9%
EPS Growth
4.4%
Profit Margin
29.6%
FCF Yield
6.3%
Debt / Equity
0.09x
ROIC
8.0%
Interest Coverage
49.01x
Current Ratio
3.57x
Dividend Yield
0.6%
Implied Growth (rev. DCF)
2.9%
Rating Score
69/100
Regeneron Pharmaceuticals (REGN) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $68.59B.
In its latest reported year it generated about $14.34B in revenue and $4.50B in net profit.
Our model rates REGN Favorable (69/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
28.0% average over the last 3 years
±9.5 pts around 36.6% across 10 years
grew in 7 of the last 9 year-over-year periods
positive in 10 of 10 years
8.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what REGN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. REGN trades near $776.43, above its 50-day average ($657.54) and 200-day average ($699.90). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 76 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. REGN's is $14.70 (~1.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month REGN found buyers near $594.90 (support) and sellers near $654.94 (resistance); its 52-week range is $529.69–$821.11. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
-2.8%
Revenue moved from $4.86B in 2016 to $14.34B in 2025, a 12.8% compound annual growth rate. The most recent year grew a steady 5.9% year over year. Slower, mature growth is common for established businesses.
Gross Margin
85.7%
Operating Margin
24.9%
Net Margin
31.4%
ROE
14.3%
Regeneron Pharmaceuticals keeps about 29.6% of each sales dollar as net profit, with a 85.7% gross margin and 24.9% operating margin. Return on equity is 14.3% and return on invested capital about 8.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$1.99B
Net Debt
-$976.40M
Net cash position
Net Debt / EBITDA
-0.27x
Debt / Equity
0.09x
Leverage: debt-to-equity is 0.1x, and operating profit covers interest about 49.0x, with a current ratio of 3.6x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $1.99B of total debt against $2.96B of cash.
Operating CF
$4.98B
Free Cash Flow
$4.08B
FCF Margin
28.4%
In the latest year Regeneron Pharmaceuticals produced about $4.98B of operating cash flow and $4.08B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
18.36x
P/S
4.48x
P/B
3.28x
EV / EBITDA
—
REGN trades at 18.4x trailing earnings (about 17.6x on estimated forward earnings), 4.5x sales, and 3.3x book value. Reverse-engineering today's price implies the market expects roughly 2.9% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$830.98
Current price
$776.43
Starting FCF (latest 10-K)
$4.08B
Growth, years 1–5
5.9%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where REGN sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How REGN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), REGN ranks #11 of 324 by our overall rating. It trades at a discount versus the sector on earnings (18.4x P/E vs. 27.3x median) with a higher return on equity (14.3% vs. 14.1%) and slower revenue growth (5.9% vs. 7.6%).
P/E vs sector
18.4x
median 27.3x
ROE vs sector
14.3%
median 14.1%
Growth vs sector
5.9%
median 7.6%
Sector rank
#11
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $776.43 today · expected CAGR -1% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $15.20B | $16.12B | $17.08B | $18.11B | $19.19B |
| Net income | $4.71B | $5.00B | $5.30B | $5.61B | $5.95B |
| EPS | $53.35 | $56.55 | $59.94 | $63.54 | $67.35 |
| Share price (low) | $586.84 | $622.05 | $659.37 | $698.94 | $740.87 |
| Share price (high) | $960.28 | $1,017.90 | $1,078.97 | $1,143.71 | $1,212.34 |
| CAGR (low–high) | -24% / 24% | -10% / 14% | -5% / 12% | -3% / 10% | -1% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for REGN:
- High net margins (29.6%) point to pricing power or efficiency.
- Healthy free-cash-flow yield (~6.3%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
- Our model's overall read is Favorable (69/100).
The case against REGN:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Regeneron Pharmaceuticals is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 18.4x earnings, which our model scores Favorable (69/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 37 Wall Street analysts covering REGN recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-9 pts of buy ratings).
Latest SEC Filings
REGN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
REGN — frequently asked questions
Is REGN a good stock to buy?
We don't give buy or sell advice. Our model rates Regeneron Pharmaceuticals Favorable (69/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is REGN's rating on The Stocks School?
Regeneron Pharmaceuticals currently scores 69/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does REGN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Regeneron Pharmaceuticals's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for REGN calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this REGN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell REGN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.